$APGE
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Michael Thomas Henderson
CEO
196
Employees
$83.03
Current Price
$3.85B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 5 | $626,864.46 | 7,500 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 6 | $806,864.46 | 9,500 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 15 | $3,265,167.50 | 39,000 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 25 | $5,292,028.03 | 66,500 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 4, 2026 | Dambkowski Carl Chief Medical Officer | Sale | 2,075 | $71.98 | $149,358.50 | View Details |
| Mar 2, 2026 | Henderson Jane Chief Financial Officer | Sale | 300 | $68.27 | $20,481.00 | View Details |
| Mar 2, 2026 | Henderson Jane Chief Financial Officer | Sale | 406 | $71.66 | $29,093.96 | View Details |
| Mar 2, 2026 | Henderson Jane Chief Financial Officer | Sale | 994 | $70.45 | $70,027.30 | View Details |
| Mar 2, 2026 | Henderson Jane Chief Financial Officer | Sale | 300 | $69.43 | $20,829.00 | View Details |
51 more transactions available โ create a free account to see 12 months of history | ||||||
Showing 21โ25 of 25 transactions
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$1.05
ActualN/A
Revenue
EstimatedN/A
ActualN/A
2 more earnings records available โ create a free account to see 12 months of history